GHP Q2 2026 Recent investments and technology advances Over the past 12 months, Weidmann Medical Technology has further strengthened its automation and digital manufacturing capabilities, particularly for diagnostics and pharmaceutical applications. One standout milestone has been the implementation of a new highly automated product line for high-precision diagnostic consumables in Bad Ragaz. In this setup, the process runs from raw material feeding to final packaging without manual operator intervention. At the same time, the company equipped new production and inspection systems in Switzerland and North America with AIsupported process monitoring and early deviation detection. This development allows process deviations to be detected early and enables remote optimisation by Weidmann Medical Technology’s engineering teams. Weidmann Medical Technology is also currently supporting a diagnostics start-up with the industrialisation of a new product that is planned to enter clinical studies by the end of 2026. Projects like this require close collaboration between development, moulding, automation, and manufacturing from an early stage, made possible through the company’s integrated structure. “Successful collaboration in medical manufacturing is not transactional,” Florian told us. “The best results are achieved when development, industrialisation, and long-term manufacturing are approached as a shared responsibility between customer and CDMO partner.” Looking ahead Looking to the future, the remainder of 2026 for Weidmann Medical Technology will focus on further expanding automation, digital manufacturing capabilities, and strategic customer programmes in diagnostics and pharmaceutical applications. The company will continue to invest in high-precision moulding technologies, AIsupported process optimisation, and integrated quality systems to further improve process stability and manufacturing efficiency. The team also sees strong potential at both its European and North American manufacturing sites, where additional production and cleanroom expansion capacity is available. As a result, Weidmann Medical Technology is actively evaluating new customer partnerships and programmes that are a strong technical and strategic fit for its operations. With a close eye on the market, the company has observed continued demand for sophisticated diagnostic consumables and pharmaceutical applications requiring highly automated, high-volume manufacturing environments. Throughout these upcoming endeavours, early collaboration with customers during development will remain an important focus, supporting efficient industrialisation and robust serial production. Leveraging more than eight decades of injection moulding expertise to deliver innovative, high-quality solutions, Weidmann Medical Technology has become a trusted partner to leading companies across the pharmaceutical, diagnostic, and medical technology sectors. The company has achieved much success over the course of its operations, with one of its most significant achievements being the successful transfer of highly sophisticated medical components into stable, automated serial production. For its exceptional work within the medical technology field, ensuring efficiency, accuracy, and scalability for demanding medical applications, we at Global Health & Pharma Magazine are delighted to recognise Weidmann Medical Technology as Switzerland’s Precision Medical Manufacturing CDMO of the Year 2026. Reflecting on the organisation’s sustained success in recent years, Florian shared, “Our success comes from consistently bridging the gap between product development and scalable industrialisation in regulated environments. Ultimately, manufacturing reliability in the medical industry is never only about efficiency or output; it directly impacts product performance, patient safety, and trust. Contact: Florian Lehner Company: Weidmann Medical Technology AG Web Address: www.weidmann-medical.com
RkJQdWJsaXNoZXIy MTUyMDQwMA==